Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Vial 10 X 250 mg/vial |
|
Dosage
For patients who do not have HIT/HITTS
PCI/PTCA: 0.75 mg/kg intravenous (IV) bolus dose followed immediately by a 1.75 mg/kg/h IV infusion for the duration of the procedure.
PCI: 0.75 mg/kg IV bolus dose followed immediately by a 1.75 mg/kg/h IV infusion for the duration of the procedure.
For patients with Consider extending duration of infusion post-procedure
up to 4 hours.
See prescribing information for full details.
Indications
Anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. The safety and effectiveness have not been established when used in conjunction with platelet inhibitors other than aspirin, such as glycoprotein IIb/IIa inhibitors. The safety and effectivenss have not been established in patients with unstable angina who are not undergoing PTCA or in patients with other acute coronary syndromes.
Contra-Indications
Known hypersensitivity to any component. Active major bleeding. Intramuscular administration.
Special Precautions
Patients with heparin-induced thrombocytopenia/heparin-induced thrombocytopenia/thrombosis syndrome (HIT/HITTS) undergoing PTCA.
Side Effects
Back pain, nausea, headache, hypotension.
Drug interactions
See prescribing information for full details.
